FUSION PHARMACEUTICALS INC's ticker is FUSN and the CUSIP is 36118A100. A total of 33 filers reported holding FUSION PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $855,057 | -44.3% | 328,868 | 0.0% | 0.00% | -60.0% |
| Q2 2023 | $1,535,814 | +23.9% | 328,868 | 0.0% | 0.01% | +25.0% |
| Q1 2023 | $1,239,832 | +19.7% | 328,868 | 0.0% | 0.00% | 0.0% |
| Q4 2022 | $1,035,934 | +11.0% | 328,868 | +6.1% | 0.00% | 0.0% |
| Q3 2022 | $933,000 | +13.9% | 310,068 | -5.7% | 0.00% | +33.3% |
| Q2 2022 | $819,000 | -69.9% | 328,868 | -6.0% | 0.00% | -72.7% |
| Q1 2022 | $2,720,000 | -37.8% | 350,000 | -66.6% | 0.01% | -35.3% |
| Q4 2021 | $4,374,000 | -35.6% | 1,048,956 | +22.3% | 0.02% | -43.3% |
| Q3 2021 | $6,795,000 | -3.9% | 858,012 | -2.0% | 0.03% | -6.2% |
| Q2 2021 | $7,071,000 | -12.1% | 875,141 | +16.7% | 0.03% | -15.8% |
| Q1 2021 | $8,040,000 | +24.4% | 750,000 | +36.4% | 0.04% | +18.8% |
| Q4 2020 | $6,463,000 | +516.7% | 550,000 | +816.7% | 0.03% | +357.1% |
| Q2 2020 | $1,048,000 | – | 60,000 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,670,516 | $9,140,000 | 2.34% |
| Pivotal bioVenture Partners Investment Advisor LLC | 1,560,982 | $3,887,000 | 1.96% |
| ADAMS STREET PARTNERS LLC | 2,947,809 | $7,340,000 | 1.91% |
| Sio Capital Management, LLC | 260,448 | $649,000 | 0.24% |
| Orbimed Advisors | 3,224,770 | $8,030,000 | 0.15% |
| Artal Group S.A. | 750,000 | $1,868,000 | 0.10% |
| TPG GP A, LLC | 2,551,794 | $6,354,000 | 0.10% |
| Perceptive Advisors | 1,052,445 | $2,621,000 | 0.08% |
| Rock Springs Capital Management LP | 809,854 | $2,017,000 | 0.06% |
| FEDERATED HERMES, INC. | 3,124,100 | $7,779,000 | 0.02% |